Brind.

Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.

2 reports, 1 independent Updated Aug 13

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.

Who's involved

What this event is mainly about

GSK Theravance Biopharma (United States)Mylan

Keep exploring

The entities involved

GSK
British multinational pharmaceutical and biotechnology company
- Clement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Mon 15:26
- GSK acquired Sierra Oncology.Mon 14:28
Theravance Biopharma (United States)
company in San Francisco, United States

Nothing else this week.
Mylan
former pharmaceutical company
- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.Mon 11:01
- Zymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Mon 11:01

Coverage

Newest first; wire copies grouped

Aug 13PR NewswireTheravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-ove
Jun 26Unknown outlet